Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNT-UHN-1 in High Risk AML
NCT03027102Phase 1Completed
- Sponsor
- University Health Network
- Start
- Aug 2017
- Primary completion
- Dec 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of DNT-UHN-1 in acute myeloid leukemia (AML) (2 arms), sponsored by University Health Network. Primary endpoint: Number of patients with adverse events and abnormal laboratory studies at 2 years. Started Aug 2017; status: completed.
02
Drugs
DNT-UHN-1
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03027102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03027102.